Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
September 21 2022 - 11:43AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2022
Commission File Number: 001-39950
Evaxion Biotech A/S
(Exact Name of Registrant as Specified in Its
Charter)
Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Furnished as Exhibit 99.1 to this Report on Form 6-K is a
press release of Evaxion Biotech A/S (the “Company”) dated September 21, 2022, announcing enrollment of first patient
in the global phase 2b clinical trial of EVX-01.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Evaxion Biotech A/S |
|
|
Date: September 21, 2022 |
By: |
/s/ Lori Hollander |
|
|
Lori Hollander |
|
|
Vice President, Financial Planning & Analysis |
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jul 2023 to Jul 2024